{"url":"https://lda.senate.gov/api/v1/filings/6b8e36da-fb3c-4be8-a774-d159cddd2eec/","filing_uuid":"6b8e36da-fb3c-4be8-a774-d159cddd2eec","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2022,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/6b8e36da-fb3c-4be8-a774-d159cddd2eec/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Erika Long","dt_posted":"2022-04-20T12:15:15-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"16 S. Lexington Street","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Arlington","registrant_state":"VA","registrant_zip":"22204","registrant":{"id":401106542,"url":"https://lda.senate.gov/api/v1/registrants/401106542/","house_registrant_id":45571,"name":"OXFORD STRATEGIES","description":null,"address_1":"16 S. Lexington Street","address_2":null,"address_3":null,"address_4":null,"city":"Arlington","state":"VA","state_display":"Virginia","zip":"22204","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ERIKA LONG","contact_telephone":"+1 202-413-0273","dt_updated":"2024-10-19T11:00:47.177218-04:00"},"client":{"id":50960,"url":"https://lda.senate.gov/api/v1/clients/50960/","client_id":50960,"name":"MALLINCKRODT LLC","general_description":"Pharmaceutical research and manufacturing","client_government_entity":null,"client_self_select":false,"state":"MO","state_display":"Missouri","country":"US","country_display":"United States of America","ppb_state":"MO","ppb_state_display":"Missouri","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2022-01-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to drug pricing and general healthcare issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139647,"prefix":"mrs","prefix_display":"MRS.","first_name":"ERIKA","nickname":null,"middle_name":null,"last_name":"LONG","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to drug pricing and general healthcare issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139647,"prefix":"mrs","prefix_display":"MRS.","first_name":"ERIKA","nickname":null,"middle_name":null,"last_name":"LONG","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to drug pricing and general healthcare issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139647,"prefix":"mrs","prefix_display":"MRS.","first_name":"ERIKA","nickname":null,"middle_name":null,"last_name":"LONG","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}